ClinicalTrials.gg
CompletedNCT04338984NESPUpdated Aug 12, 2022

Nociception-directed Erector Muscle Spinae Plane Block in Open Heart Surgery

A Phase 4 interventional study of General anesthetic and Ropivacaine 0.5% Injectable Solution in Regional Anesthesia and Heart Surgery, sponsored by Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu. Completed at 1 site in Romania. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2019, registered Apr 2020).
Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

With the advent of ultrasound (US) guidance, use of regional anaesthesia (RA) is poised to grow and evolve. Recently, cardiac surgery has benefited from newer US guided interfascial techniques as they promise to fulfil all the prerequisites of an enhanced recovery after surgery (ERAS) strategy(1,2).

The erector spinae plane (ESP) block represents such an alternative(3). Speed and ease of performance are paramount to encourage spread of its use. Hence, the scope of this trial is to investigate the effects on perioperative opioid consumption and several other secondary outcomes of a minimalist approach encompassing a bilateral single shot ESP block when applied as an adjunct to general anaesthesia.

Read the detailed description

DETAILED DESCRIPTION OF STUDY

A. Ethics

Local Ethics Committee approval and Informed Consent from patient or next-of-kin are obtained prior to study enrolment.

B. Study enrolment

Eighty adult patients scheduled for elective open cardiac surgery under general anaesthesia (GA) are randomly allocated to receive either GA plus ESP block (ESP group, n = 40) or GA alone (control group, n = 40).

C. Methods - Preinduction

  1. Premedication with intramuscular morphine 0.1mg/kg 30 minutes before induction.
  2. 16-G peripheral intravenous cannula and radial artery catheter.
  3. Five-lead ECG, pulse oximetry, non-invasive and invasive blood pressure monitoring.
  4. Analgesia monitor - the NoL index (PMD200TM, Medasense) finger probe will be connected to the index finger of the non-cannulated hand.
  5. Surgical antibiotic prophylaxis (Cefuroxime 1.5g)
  6. Stress ulcer prophylaxis (omeprazole 40 mg)

D. Methods - ESP block (intervention group only)

Before induction, patients in the intervention group are placed in sitting position under the close supervision of the attending nurse anaesthetist. After skin asepsis with chlorhexidine 2%, a high-frequency linear ultrasound probe is positioned parasagittally, 2-3 cm from midline, bilaterally, at the level of the T5 transverse process. A 25-G echogenic block needle is inserted at 20⁰-30⁰ in a caudal-to-cephalad direction until the tip of the needle reaches the interfascial plane between the erector spinae muscle and the inter-transverse ligaments. Correct hydrodissection at T5 level is first certified using normal saline. Subsequently, ropivacaine 0.5% with dexamethasone 8mg/20ml is used and maximum spread is attained by slowly advancing the needle as the interfascial plane splits up ahead. A maximum dose of 3mg/kg ropivacaine is used, corresponding to 1.5 mg/kg per side (e.g., 20 ml ropivacaine 0.5% / side for a 70kg adult). Supine position is resumed after completion of block.

E. Methods - General anaesthesia

  1. End tidal CO2 (ETCO2).
  2. Bispectral index (BIS) monitoring of hypnotic depth (target 40-60).
  3. The nociception monitor (PMD200TM, Medasense) is started after induction of general anaesthesia; a calibration period of 1-2 minutes is usually required.
  4. CVP insertion into the right internal jugular vein under ultrasound guidance. Any other hemodynamic monitor deemed useful is left at the discretion of the treating anaesthetist.
  5. Urinary catheter, rectal temperature probe placement.
  6. Intubating conditions

    6.1. Propofol 1-1.5 mg/kg or Etomidate 0.2-0.3 mg/kg.

    6.2. Fentanyl 5 mcg/kg.

    6.3. Atracurium 0.5 mg/kg.

  7. Maintenance of anaesthesia

7.1. Sevoflurane in O2 during periods of preserved pulmonary blood flow and mechanical ventilation according to BIS (see target above).

7.2. Propofol infusion according to BIS (see target above) during periods of extracorporeal support.

7.3. Atracurium 0.2-0.3 mg/kg/h for adequate neuromuscular blockade.

7.4. Management of analgesia divides in:

7.4.1. Analgesia support

7.4.1.1. ESP block in the intervention group only:

  • Theoretical duration of ESP block with surgical intensity is 4-6 hours.

7.4.1.2. Fentanyl (both study groups):

  • Analgesia monitoring (see below) provides feedback to its administration.
  • Administration follows a combination of continuous infusion and bolus dosing according to our local protocol:

    • Fentanyl 1.5 mg/50ml (30 mcg/ml).
    • Bolus dose (ml): Weight/20, which is equivalent to 1.5 mcg/kg.
    • Infusion rate (ml/hour): Weight/10, which is equivalent to 3 mcg/kg/h.
    • Last infusion rate before large vessel cannulation is maintained throughout the bypass period.

7.4.1.3. Paracetamol (both study groups):

  • Administration of 2 grams following induction of general anaesthesia.

7.4.2. Analgesia monitoring

7.4.2.1. NoL index provides a multiderivative assessment of nociception before large vessel cannulation; depending on the spontaneous cardiac rhythm, it may be expected to continue reflecting nociception even after completion of extracorporeal circulation.

  • Optimal analgesia is defined as a NoL index of 10-25.
  • Allow periods of fluctuation of less than 1 minute.
  • After sternotomy, allow a maximum fluctuation interval of 3 minutes before vital data are gathered.
  • In the ESP group, if NOL target is attained, stop fentanyl administration.

7.4.2.2. Ancillaries such as mean arterial blood pressure (MAP) and heart rate (HR) provide complementary decision loops: targets are within ± 20% of preoperative baseline.

  • During CBP they provide the only feedback on adequacy of analgesia, although highly unspecific.
  • May be used at any time to complement the NoL index.

F. Methods - Postoperatively

  1. Criteria to be met before extubation:

    1.1. Normothermia (T◦ ≥ 36◦C).

    1.2. No clinical bleeding.

    1.3. Wakefulness and RASS [-1;1].

    1.4. Hemodynamic stability with minimal vasoactive support (dobutamine \< 5 µg/kg/min and norepinephrine \< 100 ng/kg/min):

    1.4.1. MAP ≥ 60 mmHg

    1.4.2. Lactate ≤ 2 mmol/L

    1.4.3. Preserved flow (CI ≥ 2.2L/min/m2) assessed by:

    1.4.3.1. TTE any time after ICU admission

    1.4.3.2. TOE only before extubation, regardless of patient location

    1.5. Respiratory:

    1.5.1. Adequate gas exchange:

    1.5.1.1. Normocarbia.

    1.5.1.2. PaO2/FiO2 ≥ 250.

    1.5.2. Adequate effort:

    1.5.2.1. Tidal volume ≥ 5 ml/kg.

    1.5.2.2. Negative inspiratory force ≤ -20 cmH2O.

    1.5.3. Adequate airway reflex to handle secretions.

  2. Management of analgesia divides in:

2.1. Analgesia support:

2.1.1. Paracetamol 1g iv 6 hourly is standard in both groups.

2.1.2. Morphine bolus doses of 0.03 mg/kg in combination with continuous iv morphine 0.03 mg/kg/h as elicited by nociception monitoring (see below).

2.2. Analgesia monitoring

2.2.1. The visual analogue scale (VAS) is used to provide feedback on adequacy of analgesia.

2.2.2. If VAS > 3, then provision of a combination of paracetamol and morphine is warranted (see above).

02

Conditions studied

  • Regional Anesthesia
  • Heart Surgery

Keywords

  • erector spinae plane block
  • fast-track
  • rehabilitation
  • opioid
03

In context

Lead sponsor

Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Informed Consent.
  2. Elective heart surgery with sternotomy and bypass.
  3. Hemodynamic stability prior to induction (no chest pain, SAP > 100 mmHg, MAP ≥ 60 mmHg, 50 \< HR \< 100 bpm).
  4. Sinus rhythm.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy to any of the medications used in the study.
  2. BMI > 35.
  3. Patient refusal to participate in the study.
  4. Coagulopathy (INR > 1.5, APTT > 45, Fibrinogen \< 150 mg/dl).
  5. Non-elective/emergent and/or redo surgery.
  6. ASA ≥ 4.
  7. Any preoperative hemodynamic support (mechanical or pharmaceutical).
  8. Severe LV dysfunction (LVEF ≤ 30%).
  9. Severe RV dysfunction or PHT (RVFAC ≤ 25%).
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Active comparator
    General anesthesia alone (AG)

    Opioid based analgesia: Fentanyl 5 mcg/kg is standard dose at induction. Further dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline). Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol.

    Drug: General anesthetic

  • Experimental
    Erector Spinae Plane Block and General Anaesthesia (ESPAG)

    Bilateral single shot erector spinae plane block with Ropivacaine 0.5% (total dose 3mg/kg) and Dexamethasone 8mg per every 20ml Ropivacaine 0.5% is performed before induction of general anaesthesia. A minimum 30 minutes interval is allowed before skin incision. Fentanyl 5 mcg/kg is standard dose at induction; rescue dosing is steered according to NOL index and ancillaries such as heart rate and mean arterial blood pressure (± 20% of preoperative baseline). Postoperatively, analgesia comprises on-demand morphine and regularly dosed paracetamol.

    Drug: Ropivacaine 0.5% Injectable Solution

Interventions

  • DrugGeneral anesthetic

    Fentanyl is administered at induction - standard dose 5 mcg/kg. Further dosing is based on a multiderivative assessment of nociception (NOL index) and ancillaries such as heart rate and mean arterial blood pressure.

    Also known as: Fentanyl based general anaesthesia

  • Bilateral single shot erector spinae plane block is performed before induction of general anaesthesia. Ropivacaine 0.5% total dose 3mg/kg with Dexamethasone 8mg/20 ml Ropivacaine 0.5%.

    Also known as: Erector Spinae Plane Block

06

What researchers measure

Primary outcomes

  1. Intraoperative fentanyl consumption (µg/kg/h)

    Goal directed monitoring of nociception with NOL index PMD200 (+/- variation of mean arterial blood pressure and heart rate)

    Time frame: during intraoperative period

Secondary outcomes

  1. Fentanyl (µg/kg/h) consumption

    Goal directed monitoring of nociception with NOL index PMD200

    Time frame: until large vessel cannulation

  2. Morphine consumption (mg/kg)

    Postoperative opioid administration

    Time frame: 24 hours and 48 hours after surgery

  3. Quality of postoperative analgesia

    Assessment - visual analog scale (VAS) (minimum of 0, maximum of 10)

    Time frame: 6 hours, 12 hours, 24 hours and 48 hours after extubation/ICU admission and 1 hour after drain removal

  4. Time to extubation

    Following ICU admission, the time it takes to extubate the patient safely

    Time frame: up to 24 hours after surgery

  5. Norepinephrine dose (mcg/kg/h)

    Cumulative dose of Norepinephrine

    Time frame: intraoperative, 6 hours and 12 hours after surgery

  6. Time to catecholamine - free state

    Following ICU admission, the time it takes to stop all catecholamines.

    Time frame: up to 96 hours after surgery

  7. Rate of postoperative pneumonia

    Postoperative incidence

    Time frame: up to two weeks

  8. Rate of atrial fibrillation

    Postoperative incidence

    Time frame: 48 hours after ICU admission

  9. Time to first out of bed

    Time frame: up to 72 hours after surgery

  10. Rate of nausea and vomiting (PONV)

    Time frame: 24 hours after ICU admission

  11. Rate of delirium

    Time frame: 7 days after surgery

  12. Time to removal of drain

    Time frame: up to 72 hours after surgery

07

Study locations

1 site
  • Prof Dr CC Iliescu Institute for Emergency Cardiovascular Diseases
    Bucharest, 022328, Romania
08

References and documents

Publications

  • Smith LM, Barrington MJ; St Vincent's Hospital, Melbourne. Ultrasound-guided blocks for cardiovascular surgery: which block for which patient? Curr Opin Anaesthesiol. 2020 Feb;33(1):64-70. doi: 10.1097/ACO.0000000000000818. PubMed 31833864 ↗
  • Kelava M, Alfirevic A, Bustamante S, Hargrave J, Marciniak D. Regional Anesthesia in Cardiac Surgery: An Overview of Fascial Plane Chest Wall Blocks. Anesth Analg. 2020 Jul;131(1):127-135. doi: 10.1213/ANE.0000000000004682. PubMed 32032103 ↗
  • Macaire P, Ho N, Nguyen T, Nguyen B, Vu V, Quach C, Roques V, Capdevila X. Ultrasound-Guided Continuous Thoracic Erector Spinae Plane Block Within an Enhanced Recovery Program Is Associated with Decreased Opioid Consumption and Improved Patient Postoperative Rehabilitation After Open Cardiac Surgery-A Patient-Matched, Controlled Before-and-After Study. J Cardiothorac Vasc Anesth. 2019 Jun;33(6):1659-1667. doi: 10.1053/j.jvca.2018.11.021. Epub 2018 Nov 19. PubMed 30665850 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04338984
Lead sponsor
Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu
Responsible party
Balan Ion Cosmin (Consultant in Cardiovascular Anaesthesia and ICM, Institutul de Urgenţă pentru Boli Cardiovasculare Prof.Dr. C.C. Iliescu) — Principal investigator
First posted
Apr 8, 2020
Start date
Dec 1, 2019
Primary completion
Apr 30, 2021
Completion
May 31, 2021
Last update
Aug 12, 2022

Study contacts

Serban Ion Bubenek Turconi, Professor
study director · Prof. Dr. C.C. Iliescu Institute for Emergency Cardiovascular Diseases
Dana Tomescu, Professor
study director · Fundeni Clinical Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion